New AE37 scientific review
Drug evaluation
AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence
Patrick M. McCarthy ORCID Icon, G. Travis Clifton , Timothy J. Vreeland , Alexandra M. Adams , Anne E. O’Shea & George E. Peoples
Received 27 Aug 2020, Accepted 04 Nov 2020, Accepted author version posted online: 15 Nov 2020
ABSTRACT
Introduction:HER2 is a prevalent growth factor in a variety of malignancies, most prominently breast cancer. Over-expression has been correlated with poorest overall survival and has been the target of successful therapies such as trastuzumab. AE37 is a novel, HER2-directed vaccine based on the AE36 hybrid peptide (aa776-790), which is derived from the intracellular portion of the HER2 protein, and the core portion of the MHC Class II invariant chain (the Ii-Key peptide). This hybrid peptide is given with GM-CSF immunoadjuvant as the AE37 vaccine
Areas Covered:
This article describes in detail the preclinical science leading to the creation of the AE37 vaccine and examines use of this agent in multiple clinical trials for breast and prostate cancer. The safety profile of AE37 is discussed and opinions on the potential of the vaccine in breast and prostate cancer patient subsets along with other malignancies, are offered.
Expert Opinion:
Future trials utilizing the AE37 vaccine to treat other HER2-expressing malignancies are likely to see similar success, and this will be enhanced by combination immunotherapy. Ii-Key modification of other peptides of interest across oncology and virology could yield impressive results over the longer term.
I don’t have access to the full review. It’s obviously positive. This is from the Phase I and II researchers originally from the Henry Jackson Foundation for the Advancement of Military Medicine at Walter Reed.
https://www.tandfonline.com/doi/abs/10.1080/1...ode=ieid20
Drug evaluation
AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence
Patrick M. McCarthy ORCID Icon, G. Travis Clifton , Timothy J. Vreeland , Alexandra M. Adams , Anne E. O’Shea & George E. Peoples
Received 27 Aug 2020, Accepted 04 Nov 2020, Accepted author version posted online: 15 Nov 2020
ABSTRACT
Introduction:HER2 is a prevalent growth factor in a variety of malignancies, most prominently breast cancer. Over-expression has been correlated with poorest overall survival and has been the target of successful therapies such as trastuzumab. AE37 is a novel, HER2-directed vaccine based on the AE36 hybrid peptide (aa776-790), which is derived from the intracellular portion of the HER2 protein, and the core portion of the MHC Class II invariant chain (the Ii-Key peptide). This hybrid peptide is given with GM-CSF immunoadjuvant as the AE37 vaccine
Areas Covered:
This article describes in detail the preclinical science leading to the creation of the AE37 vaccine and examines use of this agent in multiple clinical trials for breast and prostate cancer. The safety profile of AE37 is discussed and opinions on the potential of the vaccine in breast and prostate cancer patient subsets along with other malignancies, are offered.
Expert Opinion:
Future trials utilizing the AE37 vaccine to treat other HER2-expressing malignancies are likely to see similar success, and this will be enhanced by combination immunotherapy. Ii-Key modification of other peptides of interest across oncology and virology could yield impressive results over the longer term.
I don’t have access to the full review. It’s obviously positive. This is from the Phase I and II researchers originally from the Henry Jackson Foundation for the Advancement of Military Medicine at Walter Reed.
https://www.tandfonline.com/doi/abs/10.1080/1...ode=ieid20
5
